The Mediaworks
191 Wood Lane White City
London W12 7FP
United Kingdom
44 20 3829 6230
https://www.autolus.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 463
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Christian Martin Itin Ph.D. | CEO & Director | 2,41M | N/D | 1964 |
Dr. Martin Pule M.D., MBBS | Founder, Senior VP & Chief Scientific Officer | N/D | N/D | 1972 |
Mr. Robert F. Dolski | Senior VP & CFO | N/D | N/D | 1971 |
Mr. Christopher Vann | Senior VP & COO | N/D | N/D | 1965 |
Mr. David Brochu | Senior VP & Chief Technical Officer | N/D | N/D | 1956 |
Mr. Alexander Swan | Senior VP & Chief Human Resources Officer | N/D | N/D | 1965 |
Mr. Brent Rice | Senior VP, Chief Commercial Officer & Site Head of US | N/D | N/D | 1966 |
Ms. Olivia Manser | Director of Investor Relations | N/D | N/D | N/D |
Mr. Alex Driggs | Senior VP of Legal Affairs & General Counsel and Secretary | N/D | N/D | N/D |
Dr. Chris Williams | Senior VP & Chief Business Development Officer | N/D | N/D | 1980 |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
L'ISS Governance QualityScore di Autolus Therapeutics plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.